Theravance

$7.99 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Theravance

Theravance Biopharma, Inc. is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company's pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting. Its commercial product VIBATIV (telavancin) is a once-daily dual-mechanism antibiotic approved in the United States and Europe for certain difficult-to-treat infections. Its Revefenacin (TD-4208) is a long-acting muscarinic antagonist (LAMA) being developed as a nebulized treatment for chronic obstructive pulmonary disease. Its neprilysin (NEP) inhibitor program is designed to develop selective NEP inhibitors for the treatment of a range of cardiovascular and renal diseases.

Stock Analysis

last close $7.99
1-mo return 18%
3-mo return -41.3%
avg daily vol. 706.28T
52-week high 22.74
52-week low 6.1
market cap. $602M
forward pe -
annual div. -
roe -
ltg forecast 54.1%
dividend yield -
annual rev. $64M
inst own. 86.7%
baraka

Subscribe now for daily local and international financial news

Subscribe